Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

17.4%

4 terminated/withdrawn out of 23 trials

Success Rate

69.2%

-17.3% vs industry average

Late-Stage Pipeline

30%

7 trials in Phase 3/4

Results Transparency

67%

6 of 9 completed trials have results

Key Signals

5 recruiting6 with results

Enrollment Performance

Analytics

Phase 2
6(42.9%)
Phase 3
5(35.7%)
Phase 4
2(14.3%)
Phase 1
1(7.1%)
14Total
Phase 2(6)
Phase 3(5)
Phase 4(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07102368Recruiting

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

Role: lead

NCT04656951Phase 2Active Not Recruiting

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

Role: collaborator

NCT04842591Active Not Recruiting

Characteristics of Pulmonary Vascular Changes in Patients With Kidney Transplantation

Role: collaborator

NCT02622581Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Role: collaborator

NCT05701150Recruiting

AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT

Role: collaborator

NCT01848028Recruiting

PsoBest - The German Psoriasis Registry

Role: collaborator

NCT04404309Recruiting

Outcomes Associated With Suicidality in Inpatients With Symptoms of Depression (OASIS-D)

Role: collaborator

NCT03399513Phase 2Completed

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT04252248Phase 1Terminated

Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage

Role: collaborator

NCT02689869Phase 2Unknown

Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Role: collaborator

NCT04810754Phase 2Unknown

An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus

Role: collaborator

NCT02951533Phase 3Completed

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Role: lead

NCT01516970Phase 3Completed

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Role: lead

NCT02395198Unknown

Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients

Role: collaborator

NCT00416273Phase 3Completed

A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

Role: lead

NCT00416208Phase 3Completed

Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma

Role: lead

NCT00833560Phase 2Completed

A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

Role: lead

NCT01667068Completed

Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up

Role: collaborator

NCT00813150Phase 3Completed

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Role: lead

NCT01009476Completed

Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine

Role: lead